Glenmark Carvedilol Lawsuit, Were You Affected? Carroll v. Glenmark Pharmaceuticals Inc., USA, No. 2:26-cv-00327

If you’ve been taking Glenmark’s generic Carvedilol for your heart — you deserve to know what was actually in those pills. Glenmark Pharmaceuticals is now facing a class action, Carroll v. Glenmark Pharmaceuticals Inc., USA, No. 2:26-cv-00327, in Washington federal court, claiming the drug was contaminated with a cancer-linked impurity. Here’s what that means for you.

Glenmark Carvedilol Lawsuit — Key Facts

Lawsuit Filed	August 4, 2026
Defendant	Glenmark Pharmaceuticals Inc., USA
Alleged Harm	Generic Carvedilol contaminated with N-Nitroso Carvedilol I, a nitrosamine impurity
Law Alleged	Washington Consumer Protection Act, breach of express and implied warranty, unjust enrichment
Who Is Affected	Nationwide purchasers of Glenmark’s Carvedilol, plus a Washington-resident subclass
Court & Case Number	U.S. District Court, Eastern District of Washington — No. 2:26-cv-00327
Current Stage	Complaint filed. No class certified. No settlement.
Lead Plaintiff Deadline	UNVERIFIED — not applicable to this type of claim
Settlement Status	Active litigation — no money, no claim form yet
Last Updated	August 25, 2026

Who Is Glenmark and Why Are They Being Sued Over Carvedilol?

Glenmark Pharmaceuticals makes the generic version of Carvedilol — sold under the brand name Coreg — at manufacturing plants in India, then distributes it in the U.S. through its New Jersey-based subsidiary. The lawsuit says this isn’t an isolated slip: it points to a documented history of manufacturing-compliance failures at Glenmark’s overseas facilities. That history is a big part of why the complaint argues this contamination wasn’t just bad luck.

What Did Glenmark Do to Carvedilol Buyers Between 2024 and 2025?

Sharon Carroll, the named plaintiff, says she bought Glenmark’s Carvedilol four separate times between March 2024 and July 2025, believing it was the same drug as brand-name Coreg — just cheaper. The complaint alleges it wasn’t. It says her pills carried an impurity called N-Nitroso Carvedilol I, a compound the FDA and international health regulators classify as a probable human carcinogen when a patient is exposed above the acceptable limit over the long term.

This wasn’t a single bad batch. FDA enforcement records show Glenmark recalled Carvedilol tablets in January 2025, again in February 2025, again in June 2025, and again in August 2025 — all for the same underlying issue. Glenmark has said the contamination came from a failure to control nitrite levels in inactive ingredients used during manufacturing. The lawsuit argues that failure could have affected every batch produced with that process, not just the specific lots officially recalled.

For more on how a recall like this can turn into a legal claim, see AllAboutLawyer.com’s coverage of the FDA’s Glenmark-linked recall list, which flagged this exact manufacturer months before this suit was filed.

Glenmark’s own recall notice said the impurity “may increase the risk of cancer” and told pharmacies to quarantine the affected product immediately. That’s not a footnote — it’s the company’s own words describing the risk to patients who’d already filled their prescriptions.

Are You Part of the Glenmark Carvedilol Lawsuit?

Here’s exactly how to know if this case includes you.

• Anyone who purchased Glenmark’s Carvedilol, in any strength, for personal or household use
• Washington residents who bought or received the drug in-state — they form a separate subclass with their own claims
• Patients whose prescriptions matched the recalled NDC codes, including 68462-0164-05 and 68462-0163-05
• People who paid a copay or full price out of pocket for the drug, regardless of whether they experienced any health effects

You likely don’t qualify if you took brand-name Coreg rather than the generic, or if your generic carvedilol came from a different manufacturer — this case is specific to Glenmark’s product.

Glenmark Carvedilol Purchasers Outside Washington — Are You Still Covered?

Yes. The complaint seeks to represent a nationwide class of everyone who paid for Glenmark’s Carvedilol, not just Washington residents. The Washington subclass exists alongside the nationwide class, not instead of it — it adds state-specific claims for in-state purchasers on top of the broader case.

Not sure if you qualify for the Glenmark Carvedilol lawsuit? A free consultation with a product liability attorney can help you sort out whether your specific prescriptions and purchases fall within the class.

What Are Glenmark Carvedilol Purchasers Asking the Court to Award?

No money yet. No claim form yet. The complaint asks the court to certify the class, and it seeks compensatory and punitive damages, plus a jury trial, on behalf of everyone who paid for the contaminated drug. Carroll’s own claims focus on getting back what she paid — the theory being that she wouldn’t have bought the drug at all, or would have paid less for it, had she known about the contamination.

What Could Glenmark Carvedilol Purchasers Receive If This Case Settles?

It’s too early to put a number on it — that depends on how many people join the class and what the litigation turns up. But the scale here is worth sitting with: FDA records tie roughly 732,960 bottles to the initial round of recalls, and Glenmark pulled more than 88,000 additional bottles in the August 2025 recall alone. That’s over 820,000 bottles pulled from pharmacy shelves in under a year, all linked to the same contamination issue — and that’s before counting anyone who took the drug and never heard about the recall at all.

Talk to a product liability attorney if you want a clearer sense of what your own purchases might be worth. Every case depends on documentation, and a lawyer can tell you what actually counts as proof.

What Should Glenmark Carvedilol Purchasers Do Right Now?

1. You don’t need to file anything today. No class has been certified, so there’s no action required yet to preserve your rights.
2. Save your pharmacy receipts, prescription labels, and any paperwork showing the NDC and lot numbers for your Carvedilol.
3. Pull your insurance statements or EOBs if you paid a copay — those documents establish what you actually spent.
4. There’s no lead plaintiff deadline reported for this case — that’s a securities-law concept, and it doesn’t apply the same way to a product contamination claim like this one.
5. Watch the docket. The case is Carroll v. Glenmark Pharmaceuticals Inc., USA, No. 2:26-cv-00327, in the Eastern District of Washington.
6. If you took the drug for an extended period or have a large purchase history, ask an attorney whether an individual claim makes more sense than waiting on the class.

Keep taking your prescribed medication unless your doctor tells you otherwise — the FDA has said stopping a heart medication abruptly carries its own real risks, and this recall was classified as a lower-severity Class II action.

Glenmark Carvedilol Lawsuit — Full Timeline

Milestone	Date
Carroll’s alleged Carvedilol purchases	March 2024 – July 2025
First Class II recall initiated (12.5 mg lots)	January 22, 2025
Second Class II recall initiated (6.25 mg/12.5 mg lots)	February 28, 2025
Third Class II recall initiated (3.125 mg/6.25 mg lots)	June 4, 2025
Fourth Class II recall initiated (multiple strengths)	August 6–7, 2025
Lawsuit filed	August 4, 2026
Next scheduled hearing	UNVERIFIED — not yet scheduled in available records
Expected resolution	UNVERIFIED — case is in early stages

Glenmark Carvedilol — Frequently Asked Questions, No. 2:26-cv-00327

Is there a class action lawsuit against Glenmark for contaminated Carvedilol right now?

 Yes. Sharon Carroll filed Carroll v. Glenmark Pharmaceuticals Inc., USA, No. 2:26-cv-00327, in the Eastern District of Washington on August 4, 2026, alleging the drug contained an undisclosed nitrosamine impurity.

Do I need to do anything right now to be part of the Glenmark lawsuit?

 No. The case hasn’t reached class certification, so there’s no claim form or deadline yet. Hold onto your receipts and prescription records in the meantime.

When will the Glenmark Carvedilol case settle?

 There’s no timeline yet — the complaint was only filed in August 2026. Pharmaceutical class actions like this one often take a year or more before any settlement is even proposed.

Can I file my own lawsuit against Glenmark instead of joining the class?

 Yes. Individual product liability claims are an option, particularly if you have strong documentation of your purchases or any health effects. An attorney can help you weigh that against joining the class.

How will I find out if the Glenmark lawsuit settles? 

Court filings are public record, and class members are typically notified by mail or email once a settlement is reached and gets preliminary court approval.

What does “lead plaintiff” mean for the Glenmark case and why does the deadline matter? 

Lead plaintiff deadlines are mainly a securities-law concept for investor class actions. Carroll is already the named plaintiff here, and no separate lead plaintiff deadline applies to this type of case.

What specific laws does Glenmark allegedly violate?

 The complaint alleges violations of the Washington Consumer Protection Act, breach of express and implied warranty, and unjust enrichment, tied to selling Carvedilol that didn’t match its represented safety and quality.

How much could Glenmark Carvedilol purchasers get if this case settles? 

No figure has been set. The claims focus on the purchase and replacement cost of the contaminated drug rather than a fixed per-person payout, and any number would depend on how the litigation and class size develop.

Sources Used in This Glenmark Carvedilol Article

• Glenmark Pharma Hit With Safety Suit After Carvedilol Recalls — Law360, August 5, 2026
• FDA Class II Recall Enforcement Report D-0216-2025, Glenmark Pharmaceuticals Inc., USA, initiated January 22, 2025 — ndclist.com recall record
• FDA Class II Recall Enforcement Report D-0450-2025, Glenmark Pharmaceuticals Inc., USA, initiated February 28, 2025 — ndclist.com recall record

Researched and written by Israr Ahmad, legal content researcher and founder of AllAboutLawyer.com. Facts verified against Law360 reporting and FDA recall enforcement records.

This article is for informational purposes only and does not constitute legal advice. Laws vary by state and individual circumstances differ. For advice about your specific situation, consult a qualified attorney.

Last Updated: August 25, 2026